Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
12. Dezember 2023 02:05 ET
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
12. Dezember 2023 02:00 ET
|
Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14. August 2023 16:05 ET
|
Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
22. Mai 2023 17:53 ET
|
Icosavax, Inc.
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
22. Mai 2023 17:37 ET
|
Icosavax, Inc.
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was generally well tolerated with no vaccine-related SAEs – – First demonstration of hMPV...
Icosavax Granted FDA Fast Track Designation for IVX-A12
21. Februar 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
06. Januar 2023 08:00 ET
|
Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15. August 2022 16:05 ET
|
Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
25. März 2022 08:00 ET
|
Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
07. Januar 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...